Company Revenue Reports

The company grew in the high single digits for 1Q22, driven by a company record for procedure volume in March.

The company grew in the high single digits for 1Q22 as its non-elective trauma business offset COVID-related elective procedure headwinds.

The company declined in the double digits for 1Q22 as it continues the early commercialization efforts of its HOLO platform.

The company's orthopedic sales grew 9% organically in 1Q22 as Bioventus targets double-digit organic growth for the full year.

The company grew in the high single-digits during a better than expected 1Q22 and restated its full-year guidance for MACI.

The company grew in the low-teens for 1Q22 as procedures rebounded, but its ongoing business model transition incurred higher costs.

The company grew 25% in the first quarter of 2022 on the strength of its expanding portfolio, salesforce and surgeon base.

The company grew in the low double digits for the first quarter of 2022 based on favorable order timing in its viscosupplement business.

The company grew in the low single digits for 1Q22 due to a tough comparison and a stagnant robotic sales pipeline.

The company grew over 60% in 1Q21 as recent acquisitions added momentum to Enovis' already impressive share gains.